A Telehealth Visit Can Satisfy Medicare's DME Face-to-Face Rule — Most Intake Files Still Can't Prove It Did

The rule everyone quotes half of

"Telehealth counts as face-to-face" has become one of those lines that gets repeated in DME intake meetings without much scrutiny. It's true, as far as it goes. Medicare's own definition treats a telehealth encounter and an in-person encounter as equivalent for satisfying the F2F requirement on items like CPAP, oxygen, and power mobility. What tends to get dropped from the sentence is everything that comes after it: the encounter has to use real-time interactive audio and video, it has to come from a practitioner actually treating that patient, and it has to produce clinical findings tied to the specific piece of equipment being ordered.

None of that is new, exactly. What's new is the volume running through that channel. Telehealth referral platforms, some of them built specifically to route DME orders, have scaled fast since the pandemic-era rules never fully reverted. A patient fills out a form, gets a video call with a practitioner they've never met before or since, and a CPAP or a brace ships two days later. On paper, a face-to-face encounter happened. Whether it would survive a payer's second look is a different question entirely.

"Telehealth satisfying the rule and telehealth documentation surviving an audit are two different claims. Most intake files only have evidence for the first one."

How we got from "flexible" to "expanded and watched"

The path here matters, because it explains why a rule that used to be fairly forgiving is now the kind of thing an auditor circles in red.

Put those two changes next to each other and the direction is obvious. Telehealth access is staying, and probably for good this time. But the law that extended it, the Preserving Telehealth, Hospital, and Ambulance Access Act, explicitly names a pattern it wants payers watching for: a practitioner or platform ordering a disproportionate amount of DME off telehealth encounters where no prior patient relationship existed. That's not a hypothetical. It's the exact shape of the brace-telemarketing schemes OIG has already traced over a billion dollars to. Suppliers who buy leads from high-volume telehealth vendors are now standing closer to that pattern than they may realize, even when every individual order is legitimate.

Not every telehealth encounter carries the same risk

The mistake most intake teams make is treating "telehealth F2F" as a single box to check. It isn't. The details of how that visit happened change the risk profile more than almost anything else in the file.

The pattern across every row is the same one that keeps showing up in DME denials generally: the paperwork itself often looks fine at a glance. It's the specifics underneath — modality, relationship, timing — that determine whether the file holds up once someone other than the person who processed it takes a second look.

The compliance line most files quietly cross

Say a mid-size CPAP supplier buys 200 qualified leads a month from a telehealth network. Each lead comes with a signed encounter note and a diagnosis. Each order, taken individually, looks like a properly documented file: physician name, date, findings, signature. Nothing about any single one raises a flag.

Now zoom out. If that same handful of practitioners on the platform is generating hundreds of DME orders a month for patients they've spoken to exactly once, that's the disproportionate-ordering pattern the newer telehealth law was written to catch. The supplier didn't fabricate anything. They just built volume on top of a channel that, in aggregate, looks like the thing regulators are watching for. That's a harder problem than a missing signature, and it's not one an intake coordinator can fix file by file on the way out the door.

"A single telehealth order rarely gets flagged on its own. It's the pattern across hundreds of them, coming from the same handful of practitioners, that does."

That's why this isn't really a "check the box" documentation gap in the way a missing DWO signature is. It requires knowing, at the portfolio level, how much of your ordering volume traces back to telehealth encounters with no prior patient relationship, and whether your practitioner mix is concentrated enough to draw a second look. Most billing systems weren't built to answer that question, because until this year, almost nobody was asking it.

Pre-submission telehealth F2F checklist

For the files in front of your team right now, here's the practical version: what to confirm before a telehealth-based order goes out the door.

What to do this week

Three things worth doing now, regardless of how your intake process is currently set up.

1. Pull your last 90 days of orders and tag which ones originated from telehealth encounters

Most supplier systems can identify this if you look, even if nobody's been tracking it as its own category. You need the denominator before you can judge the risk.

2. Check your current F2F/WOPD list against the one your intake team is actually using

The April 2026 expansion to 83 items is easy to miss if nobody updated the reference sheet taped to someone's monitor. Confirm the oxygen and oxygen-delivery additions are reflected in whatever your team checks against.

3. Ask where your telehealth-sourced volume is concentrated

Not to stop using telehealth referral channels — they're a legitimate and growing part of how care gets delivered. But knowing whether 5% or 40% of your orders trace back to a handful of practitioners with no prior patient relationship changes how carefully that volume needs to be reviewed before it becomes a claim.

Telehealth is staying. The rule that lets it satisfy a face-to-face requirement isn't going anywhere either. The question for the next two years isn't whether a video visit counts. It's whether your file can prove, on the day someone asks, that it was the kind of visit the rule actually had in mind.